The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
…the approval is based on results from the Phase 3 EXCALIBER-RRMM trial, which showed iberdomide significantly improved minimal residual disease (MRD)-negative complete response (CR) rates.
The improved post-transplantation outcomes are likely due to the introduction of novel therapeutic agents, alongside advances in donor selection, conditioning regimens, and graft-versus-host disease prophylaxis, the authors suggested.
The results showed a 30% spleen response rate and a 47% symptom response rate among evaluable patients. Overall survival reached around 37 months, which compares favorably to historical controls where survival is typically between one and three years.
The draft guidance expands frontline options for patients who are ineligible for stem cell transplants or who require oral therapies.
Isatuximab-irfc is currently approved across three indications in the US, including in combination with bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant, Sanofi reported in the release.
Dr. Jabbour details safety and efficacy findings for an olverembatinib plus blinatumomab combination in leukemia.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
![Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]](https://sohoinsider.com/wp-content/uploads/2026/06/Insider_YT_Feature_Pannunzio_CLFR2_400x40015.png)
